| |
|
|
|
|
|
|
|||
|
Blood, 15 October 2005, Vol. 106, No. 8, pp. 2798-2805. Prepublished online as a Blood First Edition Paper on July 19, 2005; DOI 10.1182/blood-2004-12-4848.
Submitted December 21, 2004
Benaroya Research Institute at Virginia Mason, Seattle, WA, USA * Corresponding author; email: jnepom{at}benaroyaresearch.org.
MHC Class II tetramer staining and activation analysis identified two distinct types of antigen-specific CD4+ T-cells in the peripheral blood of human subjects with type 1 (autoimmune) diabetes. T-cells with low avidity recognition of peptide-MHC ligands had low sensitivity to activation and inefficient activation-induced apoptosis. In contrast, high avidity T-cells were highly sensitive to antigen-induced cell death through apoptotic mechanisms, and both apoptosis-resistant high and low avidity T-cells that survived prolonged tetramer treatment were rendered anergic to restimulation by antigen. In addition, however, apoptosis-resistant high avidity T-cells acquired regulatory features, being able to suppress both antigen-specific and non-specific CD4+ T-cell responses. This suppression was contact-dependent, and correlated with the downregulation of HLA Class II and costimulatory molecules on antigen-presenting cells, including B-cells and dendritic cells. T-cells face a variety of fates following antigen exposure, including the paradoxical maintenance of high avidity autoreactive T-cells in the peripheral circulation, perhaps due to this capability of acquiring anergic and suppressive properties. Regulation via down-modulation of antigen-presenting cell function, a form of cell-to-cell licensing for suppression, also offers possibilities for the application of peptide-MHC therapeutics.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||